Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Novel approach to amoebic gill disease in salmon could benefit humans
Amoebic gill disease is a major disease of farmed Atlantic salmon.

Scientists to repurpose drugs used to treat human parasitic diseases.

Researchers at the University of Glasgow are developing a novel approach to the treatment of amoebic gill disease that could drive down the cost of drugs currently used to treat parasitic diseases in humans.

Caused by the parasite Neoparamoeba perurans, amoebic gill disease (AGD) is major disease of farmed Atrlantic salmon, resulting in severe economic losses across the world. The parasite causes proliferative gill disease, with symptoms including increased mucus on the gills, swollen tissue and breathing difficulties.

In the study, scientists propose to repurpose drugs used to treat human parasitic diseases, such as sleeping sickness, Chagas disease and leishmaniasis, to manage AGD in Atlantic salmon.

Using the University's 'drug discovery pipeline', researchers propose to test the potency of these drugs against Neoparamoeba perurans. The team will then test a candidate drug for activity against ADG in Atlantic salmon at a marine trial site in Ireland.

Researchers hope that by opening new markets for these drugs, it will drive down the cost of parasitic treatment in humans, particularly in the developing world where unaffordable healthcare can lead to millions of unnecessary deaths.

Study co-author Dr Martin Llewellyn, said: “This project is a great opportunity to understand some of the science behind symbiosis, develop a much-needed drug for salmon aquaculture and also hopefully have a beneficial impact on the treatment of diseases that impact the lives of hundreds of millions of people in the tropics.”

Funded by the BBSRC, the project will involve a collaboration with the Marine Institute, Ireland and Dalhousie University, Canada.

Become a member or log in to add this story to your CPD history

WellVet launches spring series of wellbeing talks

News Story 1
 A new spring series of wellbeing talks designed to tackle some of the issues faced in veterinary practices is launching on Saturday (27 February). Hosted by WellVet and Boehringer Ingelheim, the talks will focus on simple, practical tips to improve personal and team wellbeing.

Six 30-minute presentations will be hosted by leading coaching professionals, including Libby Kemkaran, Adrian Nelson-Pratt and occupational psychologist professor Elinor O'Connor. The events will be streamed live on the WellVet Facebook page and can be watched back at any time. For more information, visit wellvet.com 

Click here for more...
News Shorts
2021 NOAH Compendium now available

The 2021 edition of the NOAH Compendium of Data Sheets for Animal Medicines has been published.

Published annually by NOAH, this book is sent to every veterinary practice in the UK for free. The 2021 edition includes an even larger range of products than previous years.

Chief executive Dawn Howard stated that NOAH will shortly be launching a survey for practices on the Compendiums effectiveness.

She added: "Our survey will give users of the Compendium the opportunity to say how they think we can improve it to assist them in prescribing veterinary medicines and advising animal keepers on their use. We look forward to getting your views."